Key result
Ibuprofen remains the preferred therapy for symptomatic PDA in preterm infants, reserving procedures for refractory cases.
Why the study?
Management of the patent ductus arteriosus remains one of the most contentious topics in the care of preterm infants.
Population
Preterm infants with patent ductus arteriosus (PDA)
Design
Review
Authors
Loading...
May support ibuprofen as first-line for symptomatic preterm PDA; extends prior reviews but leaves optimal regimens and long-term outcomes open.
This review outlines the management of PDA in preterm infants, recommending ibuprofen as the first-line pharmacotherapy for symptomatic cases and procedural closure for refractory cases.
Mitra et al. (2022) conducted a review in Patent ductus arteriosus (PDA) in preterm infants. Pharmacotherapy (indomethacin, ibuprofen) and procedural closure was evaluated. Ibuprofen is the pharmacotherapy of choice for symptomatic patent ductus arteriosus in preterm infants, with procedural closure reserved for refractory or contraindicated cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: